Literature DB >> 7645428

Vitamin D and prostate cancer.

D Feldman1, R J Skowronski, D M Peehl.   

Abstract

Our findings demonstrate the presence of VDR in various human prostate cancer cell lines and in primary cultures derived from normal, BPH and prostate cancer. In addition, 1,25-D induced several bioresponses in these cells including growth inhibition and PSA stimulation. Based on examples in many different malignant cells as well as our data in prostate cells, that vitamin D is anti-proliferative and promotes cellular maturation, it seem clear that vitamin D must be viewed as an important cellular modulator of growth and differentiation if addition to its classical role as regulator of calcium homeostasis. In this respect, vitamin D has the potential to have beneficial actions on various malignancies including prostate cancer. Its ultimate role in prostate cancer remains to be determined, but 1,25-D may prove useful in chemoprevention and/or differentiation therapy. We believe the data currently available provide the basis for an optimistic view on the possible use of vitamin D to treat prostate cancer in patients and that further investigation is clearly warranted to better define its potential therapeutic utility.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7645428     DOI: 10.1007/978-1-4899-0949-7_5

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  7 in total

Review 1.  Prostate cancer prevention: review of target populations, pathological biomarkers, and chemopreventive agents.

Authors:  R Montironi; R Mazzucchelli; J R Marshall; P H Bartels
Journal:  J Clin Pathol       Date:  1999-11       Impact factor: 3.411

Review 2.  [Palliative systemic therapy of castration-resistant prostate cancer: current developments].

Authors:  F Finter; L Rinnab; K Gust; R Küfer
Journal:  Urologe A       Date:  2009-11       Impact factor: 0.639

3.  Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer.

Authors:  Steven Attia; Jens Eickhoff; George Wilding; Douglas McNeel; Jules Blank; Harish Ahuja; Alcee Jumonville; Michael Eastman; Daniel Shevrin; Michael Glode; Dona Alberti; Mary Jane Staab; Dottie Horvath; Jane Straus; Rebecca Marnocha; Glenn Liu
Journal:  Clin Cancer Res       Date:  2008-04-15       Impact factor: 12.531

4.  PTHrP contributes to the anti-proliferative and integrin alpha6beta4-regulating effects of 1,25-dihydroxyvitamin D(3).

Authors:  Xiaoli Shen; Ramanjaneya V R Mula; Jing Li; Nancy L Weigel; Miriam Falzon
Journal:  Steroids       Date:  2007-08-15       Impact factor: 2.668

5.  Null association between vitamin D and PSA levels among black men in a vitamin D supplementation trial.

Authors:  Paulette D Chandler; Edward L Giovannucci; Jamil B Scott; Gary G Bennett; Kimmie Ng; Andrew T Chan; Bruce W Hollis; Karen M Emmons; Charles S Fuchs; Bettina F Drake
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-06-28       Impact factor: 4.254

6.  Growth inhibition of DU-145 prostate cancer cells by a Bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl)all-trans retinamide.

Authors:  M J Campbell; M Dawson; H P Koeffler
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

7.  Synergistic inhibition of prostate cancer cell lines by a 19-nor hexafluoride vitamin D3 analogue and anti-activator protein 1 retinoid.

Authors:  M J Campbell; S Park; M R Uskokovic; M I Dawson; L Jong; H P Koeffler
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.